The global Splenomegaly Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Splenomegaly is an enlargement of the spleen.The spleen usually lies in the left upper quadrant (LUQ) of the human abdomen. Splenomegaly is one of the four cardinal signs of hypersplenism which include: some reduction in number of circulating blood cells affecting granulocytes, erythrocytes or platelets in any combination; a compensatory proliferative response in the bone marrow; and the potential for correction of these abnormalities by splenectomy.
This report aims to provide a comprehensive presentation of the global market for Splenomegaly Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Splenomegaly Therapeutics. This report contains market size and forecasts of Splenomegaly Therapeutics in global, including the following market information:
- Global Splenomegaly Therapeutics Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2022 (%)
The increasing demand for targeted therapy is one of the critical reasons that will drive splenomegaly therapeutics market growth. Targeted therapy is a novel approach used to treat malignancies without harming the peripheral healthy cells of the body. This is done by singling out and targeting the specific receptors present in cancer cells. The therapeutic benefits of this innovative approach are encouraging many institutes to increase their R&D investments in targeted therapy. The adoption of molecular-targeted therapies for the treatment of splenomegaly to reduce the spleen size will continue to improve.
We surveyed the Splenomegaly Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Splenomegaly Therapeutics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Splenomegaly Therapeutics Market Segment Percentages, by Type, 2022 (%)
- Drug Therapy
- Vaccination
- Others
Global Splenomegaly Therapeutics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Splenomegaly Therapeutics Market Segment Percentages, by Application, 2022 (%)
- Normal (Not Splenomegaly)
- Moderate Splenomegaly
- Severe Splenomegaly
Global Splenomegaly Therapeutics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Splenomegaly Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Splenomegaly Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Splenomegaly Therapeutics revenues share in global market, 2022 (%)
Key players include:
- GlaxoSmithKline plc
- Incyte Corporation
- Merck & Co., Inc.
- Novartis AG
- Sanofi
Outline of Major Chapters:
Chapter 1: Introduces the definition of Splenomegaly Therapeutics, market overview.
Chapter 2: Global Splenomegaly Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Splenomegaly Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Splenomegaly Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Splenomegaly Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Splenomegaly Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Splenomegaly Therapeutics Overall Market Size
2.1 Global Splenomegaly Therapeutics Market Size: 2022 VS 2030
2.2 Global Splenomegaly Therapeutics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Splenomegaly Therapeutics Players in Global Market
3.2 Top Global Splenomegaly Therapeutics Companies Ranked by Revenue
3.3 Global Splenomegaly Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Splenomegaly Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Splenomegaly Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Splenomegaly Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Splenomegaly Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Splenomegaly Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Splenomegaly Therapeutics Market Size Markets, 2022 & 2030
4.1.2 Drug Therapy
4.1.3 Vaccination
4.1.4 Others
4.2 By Type - Global Splenomegaly Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Splenomegaly Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global Splenomegaly Therapeutics Revenue, 2024-2030
4.2.3 By Type - Global Splenomegaly Therapeutics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Splenomegaly Therapeutics Market Size, 2022 & 2030
5.1.2 Normal (Not Splenomegaly)
5.1.3 Moderate Splenomegaly
5.1.4 Severe Splenomegaly
5.2 By Application - Global Splenomegaly Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Splenomegaly Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global Splenomegaly Therapeutics Revenue, 2024-2030
5.2.3 By Application - Global Splenomegaly Therapeutics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Splenomegaly Therapeutics Market Size, 2022 & 2030
6.2 By Region - Global Splenomegaly Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Splenomegaly Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global Splenomegaly Therapeutics Revenue, 2024-2030
6.2.3 By Region - Global Splenomegaly Therapeutics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Splenomegaly Therapeutics Revenue, 2018-2030
6.3.2 US Splenomegaly Therapeutics Market Size, 2018-2030
6.3.3 Canada Splenomegaly Therapeutics Market Size, 2018-2030
6.3.4 Mexico Splenomegaly Therapeutics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Splenomegaly Therapeutics Revenue, 2018-2030
6.4.2 Germany Splenomegaly Therapeutics Market Size, 2018-2030
6.4.3 France Splenomegaly Therapeutics Market Size, 2018-2030
6.4.4 U.K. Splenomegaly Therapeutics Market Size, 2018-2030
6.4.5 Italy Splenomegaly Therapeutics Market Size, 2018-2030
6.4.6 Russia Splenomegaly Therapeutics Market Size, 2018-2030
6.4.7 Nordic Countries Splenomegaly Therapeutics Market Size, 2018-2030
6.4.8 Benelux Splenomegaly Therapeutics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Splenomegaly Therapeutics Revenue, 2018-2030
6.5.2 China Splenomegaly Therapeutics Market Size, 2018-2030
6.5.3 Japan Splenomegaly Therapeutics Market Size, 2018-2030
6.5.4 South Korea Splenomegaly Therapeutics Market Size, 2018-2030
6.5.5 Southeast Asia Splenomegaly Therapeutics Market Size, 2018-2030
6.5.6 India Splenomegaly Therapeutics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Splenomegaly Therapeutics Revenue, 2018-2030
6.6.2 Brazil Splenomegaly Therapeutics Market Size, 2018-2030
6.6.3 Argentina Splenomegaly Therapeutics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Splenomegaly Therapeutics Revenue, 2018-2030
6.7.2 Turkey Splenomegaly Therapeutics Market Size, 2018-2030
6.7.3 Israel Splenomegaly Therapeutics Market Size, 2018-2030
6.7.4 Saudi Arabia Splenomegaly Therapeutics Market Size, 2018-2030
6.7.5 UAE Splenomegaly Therapeutics Market Size, 2018-2030
7 Splenomegaly Therapeutics Companies Profiles
7.1 GlaxoSmithKline plc
7.1.1 GlaxoSmithKline plc Company Summary
7.1.2 GlaxoSmithKline plc Business Overview
7.1.3 GlaxoSmithKline plc Splenomegaly Therapeutics Major Product Offerings
7.1.4 GlaxoSmithKline plc Splenomegaly Therapeutics Revenue in Global Market (2018-2023)
7.1.5 GlaxoSmithKline plc Key News & Latest Developments
7.2 Incyte Corporation
7.2.1 Incyte Corporation Company Summary
7.2.2 Incyte Corporation Business Overview
7.2.3 Incyte Corporation Splenomegaly Therapeutics Major Product Offerings
7.2.4 Incyte Corporation Splenomegaly Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Incyte Corporation Key News & Latest Developments
7.3 Merck & Co., Inc.
7.3.1 Merck & Co., Inc. Company Summary
7.3.2 Merck & Co., Inc. Business Overview
7.3.3 Merck & Co., Inc. Splenomegaly Therapeutics Major Product Offerings
7.3.4 Merck & Co., Inc. Splenomegaly Therapeutics Revenue in Global Market (2018-2023)
7.3.5 Merck & Co., Inc. Key News & Latest Developments
7.4 Novartis AG
7.4.1 Novartis AG Company Summary
7.4.2 Novartis AG Business Overview
7.4.3 Novartis AG Splenomegaly Therapeutics Major Product Offerings
7.4.4 Novartis AG Splenomegaly Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Novartis AG Key News & Latest Developments
7.5 Sanofi
7.5.1 Sanofi Company Summary
7.5.2 Sanofi Business Overview
7.5.3 Sanofi Splenomegaly Therapeutics Major Product Offerings
7.5.4 Sanofi Splenomegaly Therapeutics Revenue in Global Market (2018-2023)
7.5.5 Sanofi Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Splenomegaly Therapeutics Market Opportunities & Trends in Global Market
Table 2. Splenomegaly Therapeutics Market Drivers in Global Market
Table 3. Splenomegaly Therapeutics Market Restraints in Global Market
Table 4. Key Players of Splenomegaly Therapeutics in Global Market
Table 5. Top Splenomegaly Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Splenomegaly Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Splenomegaly Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Splenomegaly Therapeutics Product Type
Table 9. List of Global Tier 1 Splenomegaly Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Splenomegaly Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Splenomegaly Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Splenomegaly Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Splenomegaly Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Splenomegaly Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Splenomegaly Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Splenomegaly Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Splenomegaly Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Splenomegaly Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Splenomegaly Therapeutics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Splenomegaly Therapeutics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Splenomegaly Therapeutics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Splenomegaly Therapeutics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Splenomegaly Therapeutics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Splenomegaly Therapeutics Revenue, (US$, Mn), 2024-2030
Table 30. GlaxoSmithKline plc Company Summary
Table 31. GlaxoSmithKline plc Splenomegaly Therapeutics Product Offerings
Table 32. GlaxoSmithKline plc Splenomegaly Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. GlaxoSmithKline plc Key News & Latest Developments
Table 34. Incyte Corporation Company Summary
Table 35. Incyte Corporation Splenomegaly Therapeutics Product Offerings
Table 36. Incyte Corporation Splenomegaly Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. Incyte Corporation Key News & Latest Developments
Table 38. Merck & Co., Inc. Company Summary
Table 39. Merck & Co., Inc. Splenomegaly Therapeutics Product Offerings
Table 40. Merck & Co., Inc. Splenomegaly Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. Merck & Co., Inc. Key News & Latest Developments
Table 42. Novartis AG Company Summary
Table 43. Novartis AG Splenomegaly Therapeutics Product Offerings
Table 44. Novartis AG Splenomegaly Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. Novartis AG Key News & Latest Developments
Table 46. Sanofi Company Summary
Table 47. Sanofi Splenomegaly Therapeutics Product Offerings
Table 48. Sanofi Splenomegaly Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. Sanofi Key News & Latest Developments
List of Figures
Figure 1. Splenomegaly Therapeutics Segment by Type in 2022
Figure 2. Splenomegaly Therapeutics Segment by Application in 2022
Figure 3. Global Splenomegaly Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Splenomegaly Therapeutics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Splenomegaly Therapeutics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Splenomegaly Therapeutics Revenue in 2022
Figure 8. By Type - Global Splenomegaly Therapeutics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Splenomegaly Therapeutics Revenue Market Share, 2018-2030
Figure 10. By Type - Global Splenomegaly Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Splenomegaly Therapeutics Revenue Market Share, 2018-2030
Figure 12. By Application - Global Splenomegaly Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Splenomegaly Therapeutics Revenue Market Share, 2018-2030
Figure 14. By Region - Global Splenomegaly Therapeutics Revenue Market Share, 2018-2030
Figure 15. By Country - North America Splenomegaly Therapeutics Revenue Market Share, 2018-2030
Figure 16. US Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Splenomegaly Therapeutics Revenue Market Share, 2018-2030
Figure 20. Germany Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 21. France Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Splenomegaly Therapeutics Revenue Market Share, 2018-2030
Figure 28. China Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 32. India Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Splenomegaly Therapeutics Revenue Market Share, 2018-2030
Figure 34. Brazil Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Splenomegaly Therapeutics Revenue Market Share, 2018-2030
Figure 37. Turkey Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Splenomegaly Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 41. GlaxoSmithKline plc Splenomegaly Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Incyte Corporation Splenomegaly Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Merck & Co., Inc. Splenomegaly Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Novartis AG Splenomegaly Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Sanofi Splenomegaly Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
